APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ulcerative Colitis Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Ulcerative Colitis Medicine Market Outlook and Growth Opportunities 2026

4 January 2026194 pages

Choose your research edition.

Industry ResearchUlcerative Colitis Medicine Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Ulcerative Colitis Medicine Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Ulcerative Colitis Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ulcerative Colitis Medicine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Ulcerative Colitis Medicine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Ulcerative Colitis Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ulcerative Colitis Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ulcerative Colitis Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ulcerative Colitis Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ulcerative Colitis Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ulcerative Colitis Medicine market include Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca and Cipla, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Ulcerative Colitis Medicine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ulcerative Colitis Medicine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ulcerative Colitis Medicine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Ulcerative Colitis Medicine market.

Ulcerative Colitis Medicine Segment by Company

Sumitomo

Pfizer

Novartis

Merck

Sanofi

Johnson and Johnson

GSK

AstraZeneca

Cipla

Sun Pharm

Allergan

Teva Pharmaceutical

Ulcerative Colitis Medicine Segment by Type

5-Aminosalicylic Acid

Corticosteroids

Immunomodulator Drugs

Biologics

Ulcerative Colitis Medicine Segment by Application

Ulcerative Proctitis

Proctosigmoiditis

Left-Sided Colitis

Pancolitis

Acute Severe Ulcerative Colitis

Ulcerative Colitis Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Ulcerative Colitis Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Ulcerative Colitis Medicine key companies, revenue, market share, and recent developments.

3. To split the Ulcerative Colitis Medicine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Ulcerative Colitis Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ulcerative Colitis Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Ulcerative Colitis Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ulcerative Colitis Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ulcerative Colitis Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ulcerative Colitis Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ulcerative Colitis Medicine industry.

Chapter 3: Detailed analysis of Ulcerative Colitis Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Ulcerative Colitis Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Ulcerative Colitis Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ulcerative Colitis Medicine Industry Trends Table 2. Ulcerative Colitis Medicine Industry Drivers Table 3. Ulcerative Colitis Medicine Industry Opportunities and Challenges Table 4. Ulcerative Colitis Medicine Industry Restraints Table 5. Global Ulcerative Colitis Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ulcerative Colitis Medicine Revenue Share by Company (2021-2026) Table 7. Global Ulcerative Colitis Medicine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Ulcerative Colitis Medicine Key Company Manufacturing Base & Headquarters Table 9. Global Ulcerative Colitis Medicine Company, Product Type & Application Table 10. Global Ulcerative Colitis Medicine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Ulcerative Colitis Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 5-Aminosalicylic Acid Table 15. Significant Companies of Corticosteroids Table 16. Significant Companies of Immunomodulator Drugs Table 17. Significant Companies of Biologics Table 18. Global Ulcerative Colitis Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Ulcerative Colitis Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Ulcerative Colitis Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Ulcerative Colitis Medicine Sales Value Share by Type (2021-2026) Table 22. Global Ulcerative Colitis Medicine Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Ulcerative Proctitis Table 24. Significant Companies of Proctosigmoiditis Table 25. Significant Companies of Left-Sided Colitis Table 26. Significant Companies of Pancolitis Table 27. Significant Companies of Acute Severe Ulcerative Colitis Table 28. Global Ulcerative Colitis Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Ulcerative Colitis Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Ulcerative Colitis Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Ulcerative Colitis Medicine Sales Value Share by Application (2021-2026) Table 32. Global Ulcerative Colitis Medicine Sales Value Share by Application (2027-2032) Table 33. Global Ulcerative Colitis Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Ulcerative Colitis Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Ulcerative Colitis Medicine Sales Value Share by Region (2021-2026) Table 36. Global Ulcerative Colitis Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Ulcerative Colitis Medicine Sales Value Share by Region (2027-2032) Table 38. Global Ulcerative Colitis Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Ulcerative Colitis Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Ulcerative Colitis Medicine Sales Value Market Share by Country (2021-2026) Table 41. Global Ulcerative Colitis Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Ulcerative Colitis Medicine Sales Value Market Share by Country (2027-2032) Table 43. Sumitomo Company Information Table 44. Sumitomo Business Overview Table 45. Sumitomo Ulcerative Colitis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Sumitomo Ulcerative Colitis Medicine Product Portfolio Table 47. Sumitomo Recent Development Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Ulcerative Colitis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Pfizer Ulcerative Colitis Medicine Product Portfolio Table 52. Pfizer Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Ulcerative Colitis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Novartis Ulcerative Colitis Medicine Product Portfolio Table 57. Novartis Recent Development Table 58. Merck Company Information Table 59. Merck Business Overview Table 60. Merck Ulcerative Colitis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Merck Ulcerative Colitis Medicine Product Portfolio Table 62. Merck Recent Development Table 63. Sanofi Company Information Table 64. Sanofi Business Overview Table 65. Sanofi Ulcerative Colitis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Sanofi Ulcerative Colitis Medicine Product Portfolio Table 67. Sanofi Recent Development Table 68. Johnson and Johnson Company Information Table 69. Johnson and Johnson Business Overview Table 70. Johnson and Johnson Ulcerative Colitis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Johnson and Johnson Ulcerative Colitis Medicine Product Portfolio Table 72. Johnson and Johnson Recent Development Table 73. GSK Company Information Table 74. GSK Business Overview Table 75. GSK Ulcerative Colitis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. GSK Ulcerative Colitis Medicine Product Portfolio Table 77. GSK Recent Development Table 78. AstraZeneca Company Information Table 79. AstraZeneca Business Overview Table 80. AstraZeneca Ulcerative Colitis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. AstraZeneca Ulcerative Colitis Medicine Product Portfolio Table 82. AstraZeneca Recent Development Table 83. Cipla Company Information Table 84. Cipla Business Overview Table 85. Cipla Ulcerative Colitis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Cipla Ulcerative Colitis Medicine Product Portfolio Table 87. Cipla Recent Development Table 88. Sun Pharm Company Information Table 89. Sun Pharm Business Overview Table 90. Sun Pharm Ulcerative Colitis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Sun Pharm Ulcerative Colitis Medicine Product Portfolio Table 92. Sun Pharm Recent Development Table 93. Allergan Company Information Table 94. Allergan Business Overview Table 95. Allergan Ulcerative Colitis Medicine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Allergan Ulcerative Colitis Medicine Product Portfolio Table 97. Allergan Recent Development Table 98. Teva Pharmaceutical Company Information Table 99. Teva Pharmaceutical Business Overview Table 100. Teva Pharmaceutical Ulcerative Colitis Medicine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Teva Pharmaceutical Ulcerative Colitis Medicine Product Portfolio Table 102. Teva Pharmaceutical Recent Development Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Ulcerative Colitis Medicine Product Image Figure 2. Global Ulcerative Colitis Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ulcerative Colitis Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Ulcerative Colitis Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 5-Aminosalicylic Acid Image Figure 8. Corticosteroids Image Figure 9. Immunomodulator Drugs Image Figure 10. Biologics Image Figure 11. Global Ulcerative Colitis Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Ulcerative Colitis Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Ulcerative Colitis Medicine Sales Value Share by Type (2021-2032) Figure 14. Ulcerative Proctitis Image Figure 15. Proctosigmoiditis Image Figure 16. Left-Sided Colitis Image Figure 17. Pancolitis Image Figure 18. Acute Severe Ulcerative Colitis Image Figure 19. Global Ulcerative Colitis Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Ulcerative Colitis Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Ulcerative Colitis Medicine Sales Value Share by Application (2021-2032) Figure 22. Global Ulcerative Colitis Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Ulcerative Colitis Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Ulcerative Colitis Medicine Sales Value (2021-2032) & (US$ Million) Figure 25. North America Ulcerative Colitis Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Ulcerative Colitis Medicine Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Ulcerative Colitis Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Ulcerative Colitis Medicine Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Ulcerative Colitis Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Ulcerative Colitis Medicine Sales Value (2021-2032) & (US$ Million) Figure 31. South America Ulcerative Colitis Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Ulcerative Colitis Medicine Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Ulcerative Colitis Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • 5-Aminosalicylic Acid
  • Corticosteroids
  • Immunomodulator Drugs
  • Biologics
Applications
  • Ulcerative Proctitis
  • Proctosigmoiditis
  • Left-Sided Colitis
  • Pancolitis
  • Acute Severe Ulcerative Colitis
Companies covered
  • Sumitomo
  • Pfizer
  • Novartis
  • Merck
  • Sanofi
  • Johnson and Johnson
  • GSK
  • AstraZeneca
  • Cipla
  • Sun Pharm
  • Allergan
  • Teva Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ulcerative Colitis Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ulcerative Colitis Medicine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Ulcerative Colitis Medicine Market Dynamics
  1. 2.1 Ulcerative Colitis Medicine Industry Trends
  2. 2.2 Ulcerative Colitis Medicine Industry Drivers
  3. 2.3 Ulcerative Colitis Medicine Industry Opportunities and Challenges
  4. 2.4 Ulcerative Colitis Medicine Industry Restraints
3 Ulcerative Colitis Medicine Market by Company
  1. 3.1 Global Ulcerative Colitis Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Ulcerative Colitis Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Ulcerative Colitis Medicine Company Ranking (2024-2026)
  4. 3.4 Global Ulcerative Colitis Medicine Company Manufacturing Base and Headquarters
  5. 3.5 Global Ulcerative Colitis Medicine Company Product Type and Application
  6. 3.6 Global Ulcerative Colitis Medicine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Ulcerative Colitis Medicine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Ulcerative Colitis Medicine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Ulcerative Colitis Medicine Market by Type
  1. 4.1 Ulcerative Colitis Medicine Type Introduction
  2. 4.1.1 5-Aminosalicylic Acid
  3. 4.1.2 Corticosteroids
  4. 4.1.3 Immunomodulator Drugs
  5. 4.1.4 Biologics
  6. 4.2 Global Ulcerative Colitis Medicine Sales Value by Type
  7. 4.2.1 Global Ulcerative Colitis Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Ulcerative Colitis Medicine Sales Value by Type (2021-2032)
  9. 4.2.3 Global Ulcerative Colitis Medicine Sales Value Share by Type (2021-2032)
5 Ulcerative Colitis Medicine Market by Application
  1. 5.1 Ulcerative Colitis Medicine Application Introduction
  2. 5.1.1 Ulcerative Proctitis
  3. 5.1.2 Proctosigmoiditis
  4. 5.1.3 Left-Sided Colitis
  5. 5.1.4 Pancolitis
  6. 5.1.5 Acute Severe Ulcerative Colitis
  7. 5.2 Global Ulcerative Colitis Medicine Sales Value by Application
  8. 5.2.1 Global Ulcerative Colitis Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Ulcerative Colitis Medicine Sales Value by Application (2021-2032)
  10. 5.2.3 Global Ulcerative Colitis Medicine Sales Value Share by Application (2021-2032)
6 Ulcerative Colitis Medicine Regional Value Analysis
  1. 6.1 Global Ulcerative Colitis Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ulcerative Colitis Medicine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Ulcerative Colitis Medicine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Ulcerative Colitis Medicine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ulcerative Colitis Medicine Sales Value (2021-2032)
  7. 6.3.2 North America Ulcerative Colitis Medicine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Ulcerative Colitis Medicine Sales Value (2021-2032)
  10. 6.4.2 Europe Ulcerative Colitis Medicine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Ulcerative Colitis Medicine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Ulcerative Colitis Medicine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Ulcerative Colitis Medicine Sales Value (2021-2032)
  16. 6.6.2 South America Ulcerative Colitis Medicine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Ulcerative Colitis Medicine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Ulcerative Colitis Medicine Sales Value Share by Country, 2025 VS 2032
7 Ulcerative Colitis Medicine Country-level Value Analysis
  1. 7.1 Global Ulcerative Colitis Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ulcerative Colitis Medicine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Ulcerative Colitis Medicine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Ulcerative Colitis Medicine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Ulcerative Colitis Medicine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Ulcerative Colitis Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Ulcerative Colitis Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sumitomo
  2. 8.1.1 Sumitomo Company Information
  3. 8.1.2 Sumitomo Business Overview
  4. 8.1.3 Sumitomo Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sumitomo Ulcerative Colitis Medicine Product Portfolio
  6. 8.1.5 Sumitomo Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Ulcerative Colitis Medicine Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Ulcerative Colitis Medicine Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Ulcerative Colitis Medicine Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Ulcerative Colitis Medicine Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Johnson and Johnson
  32. 8.6.1 Johnson and Johnson Company Information
  33. 8.6.2 Johnson and Johnson Business Overview
  34. 8.6.3 Johnson and Johnson Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Johnson and Johnson Ulcerative Colitis Medicine Product Portfolio
  36. 8.6.5 Johnson and Johnson Recent Developments
  37. 8.7 GSK
  38. 8.7.1 GSK Company Information
  39. 8.7.2 GSK Business Overview
  40. 8.7.3 GSK Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GSK Ulcerative Colitis Medicine Product Portfolio
  42. 8.7.5 GSK Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Ulcerative Colitis Medicine Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
  49. 8.9 Cipla
  50. 8.9.1 Cipla Company Information
  51. 8.9.2 Cipla Business Overview
  52. 8.9.3 Cipla Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cipla Ulcerative Colitis Medicine Product Portfolio
  54. 8.9.5 Cipla Recent Developments
  55. 8.10 Sun Pharm
  56. 8.10.1 Sun Pharm Company Information
  57. 8.10.2 Sun Pharm Business Overview
  58. 8.10.3 Sun Pharm Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sun Pharm Ulcerative Colitis Medicine Product Portfolio
  60. 8.10.5 Sun Pharm Recent Developments
  61. 8.11 Allergan
  62. 8.11.1 Allergan Company Information
  63. 8.11.2 Allergan Business Overview
  64. 8.11.3 Allergan Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Allergan Ulcerative Colitis Medicine Product Portfolio
  66. 8.11.5 Allergan Recent Developments
  67. 8.12 Teva Pharmaceutical
  68. 8.12.1 Teva Pharmaceutical Company Information
  69. 8.12.2 Teva Pharmaceutical Business Overview
  70. 8.12.3 Teva Pharmaceutical Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Teva Pharmaceutical Ulcerative Colitis Medicine Product Portfolio
  72. 8.12.5 Teva Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst